Business briefs: Healthcare reform, Amgen, Pakistan pharma stance, digital marketing
September 25, 2013
5:01 pm
Despite a possible government standoff, exchanges are coming, as is a proffered rebrand; Amgen signs a university deal in China; Pakistan seeks to rein in pharma; digital marketing is on the rise, research shows
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
Business briefs: Sanofi, Alzheimer’s, and healthcare reform news
Sanofi has to provide more Aubagio data to the UK’s NICE; healthcare reform’s sixes and sevens; NIH puts money toward Alzheimer’s research
Business briefs: Biogen, Celgene, J&J, plus Obamacare TV push
September 9, 2013
5:16 pm
Biogen extend Isis relationship for six years and $100M; HHS readies healthcare reform TV push; Medivir ends hep. B clinical trial; FDA approves Celgene cancer drug; Baxter seeks Enbrel biosimilar
Employer, employee healthcare costs to rise in 2014
Benefits research studies show employers expect to lay out 7% more in healthcare costs in 2014, a move that has not been accompanied by lower employee costs.
Business briefs: Takeda, Sangamo, Catalyst, plus seniors and insurance
August 28, 2013
5:44 pm
Takeda moves an Alzheimer’s treatment to Phase III; Sangamo acquires Ceregene; Catalyst gets breakthrough designation for auto-immune disorder drug; study says seniors likely to opt out of health insurance
Business briefs: Lilly accused of bribes in China, HHS promotes healthcare reform, Novo, Herceptin biosimilar.
August 22, 2013
4:58 pm
Eli Lilly is accused of misconduct in China, Health and Human Services tries to get young adults interested in health insurance, Novo kid-friendly insulin pen approved; India biotech says its Herceptin biosimilar will launch this year.